ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of cancer. The company is developing ORIC-101, an orally administered small molecule antagonist of the glucocorticoid receptor, which is in Phase 1b/2 development for the treatment of prostate cancer. ORIC is also developing other product candidates that target other areas of cancer research, including resistance mechanisms, and the company has multiple research programs targeting other drivers of cancer growth.
ORIC Pharmaceuticals was founded in 2014 and is headquartered in South San Francisco, California. The company's mission is to discover and develop innovative cancer therapies that can help improve the lives of patients with cancer. The company's focus is on developing therapies that target the mechanisms of cancer that allow tumors to grow and spread, with the ultimate goal of improving patient outcomes and survival rates. ORIC Pharmaceuticals has partnerships with leading academic institutions and pharmaceutical companies to support the development of its pipeline of oncology therapies.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of cancer. The company is developing ORIC-101, an orally administered small molecule antagonist of the glucocorticoid receptor, which is in Phase 1b/2 development for the treatment of prostate cancer. ORIC is also developing other product candidates that target other areas of cancer research, including resistance mechanisms, and the company has multiple research programs targeting other drivers of cancer growth.